title: [Native vitamin D in dialysis patients].
abstract: Chronic kidney disease is frequent and usually responsible of mineral and bone disorder. These abnormalities lead to increased morbidity and mortality. To become active, native vitamin D needs a first hydroxylation in the liver, and a second one in the kidney. Next to its action on bone metabolism, vitamin D also possesses pleiotropic actions on cardiovascular, immune and neurological systems as well as antineoplastic activities. End-stage renal disease (ESRD) is also associated with a decrease in vitamin D activity by mechanisms including the increase of plasma phosphate concentration, secretion of FGF-23 and decrease in 1α-hydroxylase activity. The prevalence of 25 hydroxy-vitamin D deficiency depends on the chosen cut-off value to define this lack. Currently it is well established that a patient has to be substituted when 25 hydroxy-vitamin D level is under 30 ng/mL. The use and monitoring of 1.25 hydroxy-vitamin D is still not recommended in routine practice. The goals of vitamin D treatment in case of ESRD are to substitute the deficiency and to prevent or treat hyperparathyroidism. Interest of native vitamin D in first intention is now well demonstrated. This review article describes the vitamin D metabolism and physiology and also the treatment for vitamin D deficiency in ESRD population.
authors.affiliation: Service de néphrologie-dialyse, CHU Sart-Tilman, université de Liège, 4000 Liège, Belgique. Electronic address: pierre_delanaye@yahoo.fr.
authors.forename: Pierre
authors.initials: P
authors.lastname: Delanaye
authors.affiliation: Service de néphrologie-dialyse, CHU Sart-Tilman, université de Liège, 4000 Liège, Belgique.
authors.forename: Antoine
authors.initials: A
authors.lastname: Bouquegneau
authors.affiliation: Service de néphrologie-dialyse, CHU Sart-Tilman, université de Liège, 4000 Liège, Belgique.
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Krzesinski
authors.affiliation: Service de chimie clinique, CHU Sart-Tilman, université de Liège, 4000 Liège, Belgique.
authors.forename: Étienne
authors.initials: É
authors.lastname: Cavalier
authors.affiliation: Néphrologie et dialyse, Nephrocare Tassin-Charcot, Sainte-Foy-les-Lyon, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Jean
authors.affiliation: Laboratoire d'explorations fonctionnelles, Inserm U845, hôpital Necker-Enfants malades, Paris, France; Service de néphrologie et dialyse, clinique du Landy, Saint-Ouen, France.
authors.forename: Pablo
authors.initials: P
authors.lastname: Urena-Torres
authors.affiliation: Laboratoire d'explorations fonctionnelles, Inserm U845, hôpital Necker-Enfants malades, Paris, France.
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Souberbielle
mesh_terms: D000089703:Fibroblast Growth Factor-23; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D006435:Renal Dialysis; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood; D014808:Vitamin D Deficiency / Q000628:therapy
chemical_list: C000717427:FGF23 protein, human; D014807:Vitamin D; D000089703:Fibroblast Growth Factor-23; C104450:25-hydroxyvitamin D
keywords: Cholecalciferol; Cholécalciférol; Dialysis; Ergocalciferol; Ergocalciférol; Hémodialyse